Selected quotes from the press release:

Jean-Paul Clozel, Chief Executive Officer of Actelion:

“In 2010 Actelion continues to successfully implement its long-term strategy. We are advancing our existing product sales, we are moving forward with our preclinical and clinical development compounds and we are complementing our in-house efforts with external opportunities.”

Andrew J. Oakley, Chief Financial Officer of Actelion:

“Our strong operational performance – further detailed in our 2010 Half Year Report – allows me to re-affirm previous company full year 2010 guidance of total net revenue growth in local currencies of above 10 percent. Unforeseen events excluded, I now expect Non-GAAP EBIT growth - on a local currency basis - to be between 21 and 24 percent for 2010, up from close to 20 percent as previously guided. In addition to near-term performance, our organization has been further geared so as to continue operational leverage gains.”

Otto Schwarz, President of Business Operations of Actelion:

"Tracleer® continues as the treatment of choice for first-line therapy in PAH due to a combination of proven efficacy and treatment experience. Ventavis® performed very well despite new competition in the space of inhaled prostacylins as our increased strength formulation is well received by patients. I am also encouraged by the initial positive feedback from physicians on our improved formulation of intravenous epoprostenol. This is very promising for future uptake of our third PAH franchise product.”

As part of the blue-chip Swiss Market Index (SMI®) Actelion now issues a half year report. Find it here for download.